Sabby Volatility Fund Discloses 524,972 Share Stake in InMed Pharma
Ticker: INM · Form: SC 13G · Filed: Jan 4, 2024 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | SC 13G |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, insider-buy, pharmaceuticals
TL;DR
**Sabby Volatility Fund just bought 524,972 shares of InMed Pharma, signaling a big institutional bet.**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd., a Cayman Islands-based entity, reported on January 4, 2024, that it beneficially owns 524,972 shares of InMed Pharmaceuticals Inc. common stock as of December 31, 2023. This represents a significant stake, giving Sabby shared voting and dispositive power over these shares. This matters to investors because a large institutional holder taking a position can signal confidence in the company's future, potentially influencing stock price and future strategic decisions.
Why It Matters
This filing reveals a major institutional investor, Sabby Volatility Warrant Master Fund, Ltd., has acquired a substantial stake in InMed Pharmaceuticals, which could be seen as a vote of confidence and potentially attract other investors.
Risk Assessment
Risk Level: low — This filing indicates an institutional investment, which is generally a positive signal and does not inherently increase risk for current shareholders.
Analyst Insight
A smart investor would research Sabby Volatility Warrant Master Fund, Ltd.'s investment strategy and InMed Pharmaceuticals Inc.'s fundamentals to understand the rationale behind this significant stake, potentially seeing it as a positive signal for the stock.
Key Numbers
- 524,972 — Shares Beneficially Owned (Represents the total number of InMed Pharmaceuticals Inc. common stock shares held by Sabby Volatility Warrant Master Fund, Ltd.)
Key Players & Entities
- Sabby Volatility Warrant Master Fund, Ltd. (company) — reporting person and beneficial owner of shares
- InMed Pharmaceuticals Inc. (company) — the subject company whose shares were acquired
- 524,972 (dollar_amount) — number of shares beneficially owned
- December 31, 2023 (date) — date of event requiring the filing
- Cayman Islands (company) — place of organization for Sabby Volatility Warrant Master Fund, Ltd.
Forward-Looking Statements
- Other institutional investors may take notice of Sabby Volatility Warrant Master Fund, Ltd.'s position and consider investing in InMed Pharmaceuticals Inc. (InMed Pharmaceuticals Inc.) — medium confidence, target: Within the next 3-6 months
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is Sabby Volatility Warrant Master Fund, Ltd., as stated in item 1 of the filing.
What is the CUSIP number for InMed Pharmaceuticals Inc. common stock?
The CUSIP number for InMed Pharmaceuticals Inc. common stock is 457637502, as listed in the filing.
What was the date of the event that required this SC 13G filing?
The date of the event which required this filing was December 31, 2023, as specified in the filing.
How many shares of InMed Pharmaceuticals Inc. does Sabby Volatility Warrant Master Fund, Ltd. beneficially own?
Sabby Volatility Warrant Master Fund, Ltd. beneficially owns an aggregate amount of 524,972 shares of InMed Pharmaceuticals Inc., as reported in row 9 of the cover page.
What type of voting and dispositive power does Sabby Volatility Warrant Master Fund, Ltd. have over these shares?
Sabby Volatility Warrant Master Fund, Ltd. has shared voting power and shared dispositive power over all 524,972 shares, as indicated in rows 6 and 8 of the cover page.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 4, 2024 regarding InMed Pharmaceuticals Inc. (INM).